Association Between Clinical Manifestations of Covid-19 Patients Post Immunization Follow-Up (Aefi) With Cardiovascular Commorbidities and It’s Islamic Perspective Review


  • Hasyajogi Tiara Harahap
  • Lilian Batubara Universitas YARSI
  • Endy Muhammad Istiwara Universitas YARSI


COVID-19 Patients, Clinical Manifestations, Post-Immunization Adverse Events (AEFI), Cardiovascular Comorbidities


Introduction : the use of the COVID-19 vaccine can occur AEFIs which are adverse medical events and occur after immunization, but these events are not always related to the use of the vaccine. Adverse Post-Immunization Events (AEFIs) can be in the form of vaccine reactions, coincidental events, anxiety reactions, and causal relationships that cannot be determined. Post-Immunization Follow-Up Events (KIPI) COVID-19 has a different reaction, duration, symptoms and severity for everyone and not everyone experiences Post-Immunization Adjunct Events (KIPI). This study aims to determine the relationship between clinical manifestations of Post-Immunization Adverse Events (AEFI) in COVID-19 patients with cardiovascular comorbidities.

Method : This research was a descriptive observational study using a cross-sectional method. The sample in this study were 54 respondents who were COVID-19 patients at the Palmerah District Health Center who had been vaccinated 3 months after recovering from COVID-19. Data was collected by conducting direct interviews with respondents. Bivariate analysis was performed using the Chi-Square statistical test with Fisher Exact Test analysis.

Result : From the results of the analysis conducted, there were 49 respondents (90.7%) who had cardiovascular comorbidities with 45 respondents (93.8%) of whom had Post-Immunization Adjunct Events (KIPI) and 4 respondents (8.2%) who did not experience Post-Immunization Adjunct Events (KIPI). The results of the Chi-Square test with the Fisher Exact Test Analysis obtained a significance value of 0.089. Therefore, the value of Sig. (2-sided) is 0.089 (>0.05), which means that there is no association between cardiovascular comorbidities and Post-Immunization Adverse Events (AEFI).

Conclusion : There is no significant association between cardiovascular comorbidities and Post Immunization Adverse Events (AEFI).


Aisyiyah, F., 2021. Kenali dan Awasi Kejadian Ikutan Pasca Imunisasi (KIPI) Covid-19 - Promkes Dinas Kesehatan Kabupaten Klaten. [online] Promkes Dinas Kesehatan Kabupaten Klaten. Available at: <>.

Alkautsar, A., 2021. View of Hubungan Penyakit Komorbid Dengan Tingkat Keparahan Pasien COVID-19. [online] Available at: <>.

Aziz, M., Tavares, M. and Azhima, C., 2021. COVID-19 Vaccinations and the Right to Health in Indonesia: Social Justice Analysis. Lentera Hukum, 8(2), p.211.

Angeli, F. et al. (2022) “Blood pressure increase following covid-19 vaccination: A systematic overview and meta-analysis” Journal of Cardiovascular Development and Disease, 9(5), p. 150. Available at:

Barbara, L., dan Miriam, S. (2020). Safety Platform for Emergency Vaccines: Priority List of Adverse Events of Special Interest: COVID-19.

Choi, W.S. dan Cheong, H.J. (2021) “COVID-19 vaccination for people with comorbidities” Infection & Chemotherapy, 53(1). Available at:

Diyono, dan Kristanto, B. (2021). Comorbid Factors Covid-19 In Indonesia: Scopyng Review. Kosala : Jurnal Ilmu Kesehatan.

Gandryani, F. dan Hadi, F. (2021) “Pelaksanaan Vaksinasi covid-19 di Indonesia: Hak Atau Kewajiban Warga Negara,” Jurnal Rechts Vinding: Media Pembinaan Hukum Nasional, 10(1), p. 23. Available at:

Getachew, B. dan Tizabi, Y. (2021) “Vitamin D and Covid?19: Role of Ace2, age, gender, and ethnicity” Journal of Medical Virology, 93(9), pp. 5285–5294. Available at:

Kaur, R. et al. (2022) “Cardiovascular adverse events reported from covid-19 vaccines: A study based on who database” International Journal of General Medicine, Volume 14, pp. 3909–3927. Available at:

Kemenkes RI. (2021). Buku Saku Tanya Jawab Seputar Vaksinasi COVID-19 (1st ed.). Kementerian Kesehatan Republik Indonesia.

Nikpouraghdam, M. et al. (2020) “Epidemiological characteristics of Coronavirus Disease 2019 (COVID-19) patients in Iran: A single center study” Journal of Clinical Virology, 127, p. 104378. Available at:

Pramesti, T., Trisnadewi, N. W., Lisnawati, K., Idayani, S., & Sutrisna, I. G. (2021). Peningkatan Pengetahuan Masyarakat tentang Vaksinasi Covid-19 melalui Edukasi tentang Kejadian Ikutan Pasca Imunisasi (KIPI) . Prosiding Seminar Nasional Pengabdian Kepada Masyarakat: Peduli Masyarakat, 1(1), 165-172.

Remlabeevi, A. et al. (2021) Adverse events and their association with Comorbidities after first and second doses of Covishield vaccination among healthcare workers of government owned Medical Colleges in Kerala, medRxiv. Cold Spring Harbor Laboratory Press. Available at: (Accessed: December 12, 2022).

SeyedAlinaghi, S.A. et al. (2022) Safety and adverse events related to COVID-19 mrna vaccines; a systematic review, Archives of academic emergency medicine. U.S. National Library of Medicine. Available at: (Accessed: December 12, 2022).

Utami, W. et al. (2022) Adverse Events Following Immunization (AEFI) of COVID-19 vaccines and their association with comorbidities in health personnel and public servants in Indonesia. Public Health of Indonesia.

World Health Organization (WHO) (2021) Covid-19 vaccines technical documents, COVID-19 Vaccines Technical Documents. World Health Organization. Available at: (Accessed: December 12, 2022).

World Health Organization (WHO) (2021) The different types of covid-19 vaccines, World Health Organization. World Health Organization. Available at: (Accessed: December 21, 2022).

Wu, C. et al. (2020) “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China” JAMA Internal Medicine, 180(7), p. 934. Available at:

Yulyani, V., et al. (2022) Gambaran Status Demografi, Penyakit Komorbiditas Dan Kejadian Ikutan Pasca Imunisasi (KIPI) Pada Tenaga Kesehatan Setelah Vaksin Covid-19 Di RSUD Abdul Moeloek. Malahayati Nursing Journal, 4(6), pp.1387-1398.